Eva Neunhoeffer
University of Tübingen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Eva Neunhoeffer.
Proceedings of the National Academy of Sciences of the United States of America | 2008
Carlo Pergola; Gabriele Dodt; Antonietta Rossi; Eva Neunhoeffer; Barbara Lawrenz; Hinnak Northoff; Bengt Samuelsson; Olof Rådmark; Lidia Sautebin; Oliver Werz
5-Lipoxygenase initiates the biosynthesis of leukotrienes, lipid mediators involved in normal host defense and in inflammatory and allergic disorders. Despite an obvious gender bias in leukotriene-related diseases (e.g., asthma), gender aspects have been neglected in studies on leukotrienes and 5-lipoxygenase. Here, we show that leukotriene formation in stimulated whole blood or neutrophils from males is substantially lower compared with females, accompanied by changed 5-lipoxygenase trafficking. This is due to gender-specific differential activation of extracellular signal-regulated kinases (ERKs). The differences are directly related to variant male/female testosterone plus 5α-dihydrotestosterone levels, and addition of 5α-dihydrotestosterone to female blood or neutrophils reduced the high (female) LT biosynthesis capacity to low (male) levels. In conclusion, regulation of ERKs and leukotriene formation by androgens constitutes a molecular basis for gender differences in the inflammatory response, and in inflammatory diseases such as asthma.
Lupus | 2012
Melanie Henes; Joerg Henes; Eva Neunhoeffer; M Von Wolff; M Schmalzing; I Kötter; Barbara Lawrenz
Objectives: Despite new treatment options, some patients with systemic lupus erythematosus (SLE) need to be treated with the cytotoxic agent cyclophosphamide (CYC). Unlike malignant disease, there are no recommendations for ovarian protection in SLE. The clinical experience of the FertiPROTEKT network as well as recommendations after literature review will be presented in this paper. Methods: Retrospective analyses of counselling and treatment data from the FertiPROTEKT register with special respect to SLE patients under 40 years prior to planned CYC treatment. Results: A total of 2836 patients were advised prior to cytotoxic treatment in one of the FertiPROTEKT centres during January 2007 to November 2011. Of those, 68 patients (mean age 25 +/− 6.07years) were counselled for severe SLE. Only five women did not make use of a fertility preservation method. Sixty-three patients (92.6%) decided in favour of a fertility preservation method. The largest proportion (91.2%) opted for treatment with a GnRH analogue. Ovarian tissue removal for cryoconservation was performed in 16 patients (25%). Stimulation therapy for cryoconservation of fertilized egg cells was performed in three patients (4.4%). Conclusions: When counselling patients with SLE for fertility preservation one has to be aware of the disease-specific risks. According to the literature, a safe and effective option in SLE up to now has been the use of a GnRH analogue. Cryoconservation of ovarian tissue must still be seen as an experimental treatment, but as data on removal, cryoconservation, retransplantation and pregnancies are steadily rising, this presents a promising option for young SLE patients. Cryoconservation of oocytes must be very critically evaluated due to the need for a stimulation therapy and should only be performed after particular consideration of the individual risks.
Onkologie | 2012
Barbara Lawrenz; Melanie Henes; Eva Neunhoeffer; Tanja Fehm; Stephanie Huebner; Lothar Kanz; Patricia Marini; Frank Mayer
Over the last decade, advances in oncology led to improved treatment results and increasing numbers of long-term cancer survivors. Fulfilling the desire to have children is important for many patients after cancer treatment. Consequently, oncologists, gynecologists and obstetricians are seeing more patients who wish to conceive after treatment. The necessary prerequisites that should be considered when supporting a planned pregnancy after cancer treatment are discussed in this article. The possible consequences of chemotherapy and radiotherapy on the course of pregnancy and the health of the offspring, as well as the interactions between cancer and pregnancy, are reviewed with the focus on childhood cancer, malignant lymphomas, and breast cancer. Despite chemo- or radiotherapy, neither the teratogenic risk nor the risk of adventitious cancers appears to be increased for the offspring of cancer survivors. However, there is a slightly higher risk of miscarriage after chemotherapy. In case of radiation to the uterus, there is a higher risk of premature birth, intrauterine growth retardation, and increased perinatal mortality. The effect is more pronounced after prepubertal radiation than for postpubertal radiation. The former cancer patient’s desire to conceive can nevertheless be supported, given that pregnancy and birth are closely monitored.
Onkologie | 2011
Barbara Lawrenz; Tanja Fehm; Eva Neunhoeffer; Bernhard Krämer; Martin Soekler; Lothar Kanz; Melanie Henes; Frank Mayer
Background: High cure rates in women suffering from Hodgkin’s disease or aggressive non-Hodgkin’s lymphoma are often achieved at the cost of impaired ovarian function or infertility. Different strategies can be offered to protect fertility. Early experiences with the implementation of a specialised fertility preservation clinic are analysed with the aim to assess the need for and acceptance of the clinic, as well as the delay of treatment caused by the different approaches. Available options are reviewed. Patients and Methods: Data on underlying malignancy and fertility preservation measures in women of childbearing age treated for aggressive lymphoma and Hodgkin’s disease with curative intent between November 2006 and January 2010 were retrospectively analysed. Results: Among 111 female lymphoma patients, 30 were eligible for counselling. Nineteen accepted the offer. The main reason for declining was completed family planning. Eight further patients were referred from elsewhere. Of the counselled patients, 96% decided to pursue at least 1 protective strategy, 39% chose an invasive procedure (cryopreservation of ovarian tissue or oocyte aspiration following hormonal stimulation). These procedures deferred the start of systemic treatment within the expected range, no undue delays were observed. Conclusions: Female lymphoma patients have a large demand for counselling about measures to protect fertility. In a proper setting, counselling and intervention can be offered without undue delays menacing the chance for cure.
Journal of Laparoendoscopic & Advanced Surgical Techniques | 2006
Sven Richter; Otto Kollmar; Eva Neunhoeffer; Martin K. Schilling; Michael D. Menger; Georg A. Pistorius
Fertility and Sterility | 2007
Christian W. Wallwiener; Markus Wallwiener; Eva Neunhoeffer; Michael Menger; Keith B. Isaacson; Wolfgang Zubke
Archives of Gynecology and Obstetrics | 2010
Barbara Lawrenz; Eva Neunhoeffer; Melanie Henes; S. Lessmann-Bechle; Bernhard Krämer; Tanja Fehm
Archives of Gynecology and Obstetrics | 2011
Barbara Lawrenz; Malgorzata Banys; Melanie Henes; Eva Neunhoeffer; Eva-Maria Grischke; Tanja Fehm
Women's Health | 2011
Barbara Lawrenz; Melanie Henes; Eva Neunhoeffer; Bernhard Kraemer; Tanja Fehm
Geburtshilfe Und Frauenheilkunde | 2010
Barbara Lawrenz; Eva Neunhoeffer; Melanie Henes; Tanja Fehm